Abstract. Apoptosis is closely associated with the occurrence and development of cardiovascular diseases and is considered as one of the crucial pathological processes of cardiomyopathy, sepsis, ischemia/reperfusion injury, myocardial infarction and heart failure. Hesperetin (HES), a flavanone glycoside found in citrus fruit peels, has been known to exhibit several key biological and pharmacological properties. Previous studies have demonstrated the anti-inflammatory, anti-oxidant and anti-tumor functions of HES. However, with regards to the pro- or anti-apoptotic functions of HES, there are several disagreements within the literature. To examine whether HES has protective effects in cardiac apoptosis, the present study examined the role of HES in lipopolysaccharide (LPS)-stimulated H9C2 cardiomyocytes, aiming to clarify the possible mechanisms underlying its effects. In the present study, HES reduced the percentage of viable apoptotic (VA) cells in a flow cytometry analysis. It had an anti-apoptosis function in LPS-stimulated H9C2 cells. To clarify whether HES alleviated LPS-stimulated apoptosis through the mitochondria-dependent intrinsic apoptotic pathway, certain indicators of this pathway were detected, including members of the caspase family. The data revealed that HES attenuated the activation of caspase-3 and caspase-9. These results indicated HES has a mitochondria-dependent anti-apoptosis effect in LPS-stimulated H9C2 cells. To explore the possible mechanisms, the protein expression levels of certain markers in the possible signaling pathway were detected, including JNK and Bcl-2 family. As a result, HES downregulated the protein expression of Bax, upregulated the expression of Bcl-2 and attenuated the phosphorylation level of JNK. Therefore, the anti-apoptosis effects of HES were possibly mediated by the JNK/Bax signaling pathway. In conclusion, HES has a mitochondria-dependent anti-apoptosis effect in LPS-induced H9C2 cells via the JNK/Bax signaling pathway.

Introduction
Cardiomyopathy is a major focus of studies investigating cardiovascular diseases (1-3). Accumulating evidence suggests that the apoptotic and inflammatory responses of cardiomyocytes are the crucial processes of cardiomyopathy. Inflammation and apoptosis of cardiomyocytes is a key feature of a variety of pathological conditions in various cardiovascular diseases, including sepsis, ischemia/reperfusion injury, myocardial infarction and end-stage heart failure (3-6). The traditional therapies preventing inflammatory responses and apoptosis of cardiomyocytes remain ineffective, so studies have focused on novel strategies (7-11).

Hesperetin (HES), a flavanone glycoside, has been found in citrus fruit peels. Previous studies have demonstrated that HES has significant anti-inflammatory, anti-oxidant and anti-tumor effects (12-14). However, there are several divergences in the literature, with regards to the effect of HES on apoptosis. A number of studies revealed that HES rescues cells from apoptosis (15), while others described its pro-apoptotic effects (16,17). Whether HES may prevent apoptosis in cardiomyocytes, particularly following an inflammatory response, remains unclear.

Lipopolysaccharide (LPS), known as bacterial endotoxin, is a constituent of the bacterial cell wall which is able to induce inflammatory responses. Numerous studies indicate that LPS contributes to inflammation and apoptosis (18-20), and can induce inflammation and apoptosis in cardiomyocytes (18,19).

In the present study, LPS was utilized to induce apoptosis in the H9C2 cardiomyocytes, in an attempt to clarify whether HES has protective effects on LPS-induced H9C2 cell apoptosis, and to identify the possible mechanisms underlying these effects.

Materials and methods
Hesperetin attenuates mitochondria-dependent apoptosis in lipopolysaccharide-induced H9C2 cardiomyocytes
ZHENG YANG1,2*, YUAN LIU1,2*, WEI DENG1,2, JIA DAI1,2, FANGFANG LI1,2, YUAN YUAN1,2, QINGQING WU1,2, HENG ZHOU1,2, ZHOUYAN BIAN1,2 and QIZHU TANG1,2
1Department of Cardiology, Renmin Hospital of Wuhan University; 2Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China
Received November 9, 2013; Accepted February 27, 2014
DOI: 10.3892/mmr.2014.2002

Correspondence to: Professor Qizhu Tang, Department of Cardiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, Hubei 430060, P.R. China
E-mail: qztang@whu.edu.cn

*Contributed equally

Key words: hesperetin, apoptosis, cardiomyopathy, mitochondria, lipopolysaccharide
(DMEM)/F12 1:1 medium, 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) were obtained from Gibco Life Technologies (Carlsbad, CA, USA). The cell counting kit-8 (CCK-8) was from Dojindo (Kumamoto, Japan). The BCA protein assay kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The primary antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA) and the secondary antibodies were from LI-COR Biosciences (Lincoln, NE, USA). Caspase 3 Activity kit was acquired from Beyotime Institute of Biotechnology (Shanghai, China) and Caspase-9 Colorimetric Assay kit was from Nanjing KeyGen Biotech. Co. Ltd (Nanjing, China).

**Cell culture and treatment.** The rat cardiomyocyte-derived cell line H9C2 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). H9C2 cells were cultured in DMEM/F12 medium containing 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml), and maintained at 37°C in a humidified incubator (SANYO 18M) with 5% CO₂. Cells were split 1 to 3 at 70-80% confluence. Cells were cultured with serum-free DMEM for 24 h prior to stimulation and then were seeded at a density of 1x10⁶/well onto six-well culture plates for mRNA extraction and 1x10⁷/well onto 100 mm culture dishes for protein extraction.

**Cell cytotoxicity test.** The cell viability was determined by the CCK-8 assay. Following stimulation with different concentrations of HES for 12 h, 10 µl of CCK-8 solution was added to each well of the 96-well plates. Following a 4 h incubation, the absorbance of every well was measured at 450 nm using a microplate reader (Synergy HT; BioTek Instruments, Inc., Winooski, VT, USA). The cell viability in the control medium without any treatment was represented as 100% and the cell viability percentage of each well was calculated.

**Flow cytometry analysis of early apoptotic cells.** To detect the viable apoptotic (VA) cells, the Annexin V Apoptosis kit was used. The H9C2 cells were stimulated by different concentrations of HES (0, 6.25, 12.5, 25, 50 µM) together with LPS (10 µg/ml) for 12 h. Then, the cells were collected and resuspended in the binding buffer. Following the addition of Annexin V and PI, the cells were assayed by the Fluorescence Activated Cell Sorter (FACSCalibur Flow Cytometer; BD Biosciences (San Jose, CA, USA).

**Caspase-3 and caspase-9 activity assay.** The activity of caspase-3 was measured by the Caspase 3 Activity kit and caspase-9 by the Caspase-9 Colorimetric Assay kit. To detect the activity of caspase-3, the sample and Ac-DEVD-pNA (2 mM) were added into the buffer solution. Following an 2 h incubation in 37°C, the optical density (OD) was detected at 405 nm and the caspase-3 activity of the sample was calculated. In examining the caspase-9 activity, the sample (50 µl) and caspase-9 substrate (5 µl) were added into a 2X reaction buffer (50 µl). Following 4 h incubation in 37°C, the A405 OD was detected and the caspase-9 activity of sample was calculated.

**Western blot analysis.** The H9C2 cells were incubated in 10 µg/ml LPS for 0, 0.5, 1 and 2 h in the absence or presence of HES and were lysed in a RIPA lysis buffer. Then, the concentration of the protein was measured using the BCA protein assay kit in the Synergy HT instrument (BioTek Instruments, Inc.) and the concentration of the samples was calibrated. Equal amounts (15/lane) of protein samples were loaded onto 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then blotted onto an Immobilon-FL membrane (Millipore, Bejing, China) using a Gel Transfer Device (Invitrogen Life Technologies, Carlsbad, CA, USA). Following this, the membranes were blocked within 5% non-fat milk dissolved in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) for >2 h at room temperature. Then, the membranes were incubated separately with primary antibodies, including JNK and phospho-JNK, Bax, Bcl-2 and GAPDH antibodies (1:1000 dilution) overnight at 4°C. Following three washes in TBS-T, the membranes were incubated in the secondary antibodies, goat anti-rabbit IgG or goat anti-mouse IgG for 1 h. At last, the membranes were scanned by the Odyssey infrared imaging system (LI-COR Biosciences) to quantify the protein expression.

**Statistical analysis.** The data are expressed as the mean ± SEM (standard error of mean). Statistical analysis of the data was conducted by one-way analysis of variance (ANOVA) followed by Tukey post hoc test. P<0.05 were considered to indicate a statistically significant difference.

**Results**

Hesperetin affects cell viability in LPS-treated H9C2 cells. A cell cytotoxicity test was used to detect the potential cytotoxicity of HES. The cell viabilities were evaluated by an CCK-8 assay. The H9C2 cardiomyocytes were incubated in the culture medium separately with different concentrations of HES (12.5, 25, 50 µM). The cell viabilities in HES-treated cells were reduced by ~20%, as compared with the control group. HES had moderate effects on the viability of the H9C2 cells at different concentrations (Fig. 1) and it was concluded...
that the variable concentration of HES has a weak effect on the activity of H9C2 cells.

**Hesperetin reduces the percentage of VA cells in LPS-treated H9C2 cells.** To clarify whether HES affects apoptosis, the changes of VA cells were examined by flow cytometry analysis. Following stimulation by LPS (10 µg/ml) with different doses of HES (0, 6.25, 12.5, 25 µM), the percentages of viable cells increased markedly and the percentages of VA cells were decreased sharply in HES-treated cells, as compared with the LPS group. (A) Stimulated by LPS only, the percentage of VA cells was 57.4%; (B) stimulated by LPS and 6.25 µM HES, the percentage of VA cells dropped to 47.2%; (C) when stimulated by LPS and 12.5 µM HES, the percentage of VA cells dropped to 43.7%; (D) when the dose of HES up to 25 µM, the percentage of VA cells declined to 25.8%. HES, hesperetin; VA, viable apoptotic; LPS, lipopolysaccharide.

Figure 2. Effect of HES on the VA cells. Upper right, Annexin V+/PI+ (necrotic cells); lower right, Annexin V+/PI− (VA cells); lower left, Annexin V+/PI− (viable cells). The H9C2 cells were stimulated by LPS (10 µg/ml) with different doses of HES (0, 6.25, 12.5, 25 µM), the percentages of viable cells increased markedly and the percentages of VA cells were decreased sharply in HES-treated cells, as compared with the LPS group. (A) Stimulated by LPS only, the percentage of VA cells was 57.4%; (B) stimulated by LPS and 6.25 µM HES, the percentage of VA cells dropped to 47.2%; (C) when stimulated by LPS and 12.5 µM HES, the percentage of VA cells dropped to 43.7%; (D) when the dose of HES up to 25 µM, the percentage of VA cells declined to 25.8%. HES, hesperetin; VA, viable apoptotic; LPS, lipopolysaccharide.

![Figure 2](image_url)

Figure 3. Effects of HES on the activities of caspase-3 and caspase-9. (A) Following stimulation by LPS, the activity of caspase-3 increased markedly and peaked at 8 h. (B) The activity of caspase-3 reduced significantly following 8 h HES treatment. (C) The activity of caspase-9 increased following LPS stimulation and peaked at 2 h. (D) The activity of caspase-9 decreased markedly at 2 h in the HES treated cells. *P<0.05 vs. the control group; †P<0.05 vs. the LPS group. HES, hesperetin; LPS, lipopolysaccharide.

![Figure 3](image_url)
of VA cells decreased most apparently, it decreased from 57.4% in the LPS-stimulated cells to 25.8% (Fig. 2). Therefore, it was concluded that HES had an anti-apoptosis effect on LPS-stimulated H9C2 cells.

Hesperetin reduces the activities of caspase-3 and caspase-9. In order to clarify whether HES alleviated LPS-stimulated apoptosis through the mitochondria-dependent intrinsic apoptotic pathway, the activity of a number of the members of the caspase family, which have important roles in apoptosis, including caspase-3 and caspase-9, was examined. Caspase-3 is an effector in apoptosis and caspase-9 is a crucial marker of mitochondria-dependent intrinsic apoptotic pathway. To identify the optimal stimulating time, the activities of caspase-3 and -9 in LPS-induced cells at different times (0, 2, 4, 6, 8, 12 h) were assayed. Following stimulation by LPS, the activity of caspase-3 increased markedly and peaked at 8 h (Fig. 3A). Then, the cells were incubated in LPS medium with and without HES for 8 h. Following this, the activities of caspase-3 with and without HES treatment were compared. The activity reduced significantly following HES treatment (Fig. 3B). For caspase-9, the activity increased also following LPS stimulation and peaked at 2 h (Fig. 3C). The cells were cultured for 2 h, and the results indicated the activity of caspase-9 decreased markedly at 2 h in HES treated cells (Fig. 3D).

Hesperetin alleviates mitochondria-controlled apoptosis via JNK/Bax pathway. To examine the possible mechanisms of the anti-apoptosis effects of HES on LPS-stimulated H9C2 cells, the protein expression of certain markers in the associated signaling pathway were detected. The phosphorylation of JNK has a crucial role in the phase of apoptosis. Bax and Bcl-2 are important indicators of the mitochondria-controlled apoptotic pathway (21). In the present study, these markers were detected using western blot analysis. The H9C2 cells were incubated in 25 µM HES for different times (0, 0.5, 1, 2 h) in the absence of LPS, and the protein expression of JNK, Bax, and Bcl-2 were detected (Fig. 4). LPS upregulated the protein levels of phospho-JNK and HES blocked the phosphorylation of JNK. *P<0.05 vs. the control group; *P<0.05 vs. the LPS group at the same time point. HES, hesperetin; LPS, lipopolysaccharide.
or presence of 10 µg/ml LPS. As a result, LPS upregulated the protein levels of phospho-JNK. Following HES treatment, the level of phospho-JNK was downregulated (Fig. 4E and F). The protein level of Bax was increased over time when stimulated by LPS only and decreased in the HES-treated groups (Fig. 4A and B). When stimulated by LPS only, the level of Bcl-2 reduced at 0.5 h (this change was not significantly different), and had no significant changes at the other time points. When HES was added the trend was opposite, in that the level of Bcl-2 increased markedly (Fig. 4C and D).

Discussion

A significant finding of the present study was that HES significantly attenuated the mitochondria-controlled apoptosis in H9C2 cardiomyocytes stimulated by LPS. Furthermore, the JNK/Bax signaling pathway had an important role in these processes. These data suggested that HES effectively attenuates LPS-stimulated apoptosis in cardiomyocytes via the suppression of the JNK/Bax-dependent signaling pathway.

Inflammatory responses and apoptosis have a considerable role in the pathogenesis of multiple cardiovascular diseases, including cardiomyopathy, cardiac hypertrophy, HF, atherosclerosis, ischemia/reperfusion injury and others (6,22-24). Anti-inflammatory and anti-apoptotic agents are highly beneficial in the treatment of these pathological processes. A number of components extracted from plants have anti-inflammatory functions, including Gastrodin and Carthamus tinctorius L. (25,26). HES, a flavonoid from citrus fruits, widely used in traditional Chinese medicine, also appears to have anti-inflammatory properties. In our pre-experiment, HES markedly decreased the mRNA expression levels of IL-1β, IL-6 and TNF-α in LPS-stimulated H9C2 cells. Furthermore, a number of studies have also demonstrated that HES may decrease the expression of certain pro-inflammatory cytokines, including IL-1β, matrix metalloproteinase (MMP)-3, IL-6 and others in various different cells (27). The anti-inflammatory function of HES has been widely accepted, so the present study instead focused on defining the potential anti-apoptotic functions of HES.

Apoptosis is another mediator of the pathogenesis of cardiac dysfunction, cardiac injury, and in the pathological changes in cardiovascular disease. It has been demonstrated that anti-inflammatory and anti-apoptotic agents are notably beneficial in the treatment of these types of conditions (28,29). Though previous studies have proved a certain anti-inflammatory function of HES, whether HES has an anti-apoptosis or pro-apoptosis function remains unclear. A number of studies have demonstrated that HES may be potentially toxic to H9C2 cells. It was considered that this result may possibly be due to the dose of HES at the start of the experiment. However, a similar result was found in another HES study, that observed that when the dose of HES reached 60 µM, the cell viability decreased significantly (16). Despite this, in another study, HES did not markedly affect the growth of preadipocytes at a dose of 100 µM (17). Therefore, this possibility should be excluded. Following further investigation of the literature, it was considered that this phenomenon may be cell-type dependent, and different cells may have different tolerances for HES. It is therefore hypothesized that at certain concentrations, HES has anti-apoptosis and pro-apoptosis effects in different cells. Another divergence in the results, in Fig. 4E and F, was that the phosphorylation level of JNK was upregulated at 0.5 h following HES-treatment. This is possibly caused by the potential toxicity of HES, or the experimental manipulations had an impact on the condition of the cells. To a certain extent, all of these concerns may be attributed to the potential pro-apoptosis effect of HES.

In conclusion, the present study provides the first evidence demonstrating that HES has protective effects on LPS-stimulated apoptosis in H9C2 cardiomyocytes. The anti-apoptosis function of HES is mediated through the mitochondria-dependent intrinsic apoptosis via JNK/Bax-dependent signaling pathway. These findings further our understanding of the pharmacological effect of HES and the pathways exerting its protective effects. HES may promote the development of novel therapeutic strategies for the treatment of inflammatory injury and apoptosis in cardiovascular diseases.

Acknowledgements

The present study was supported by the Fundamental Research Funds for the Central Universities of China (201202020211).

19. Hou Y and Liu H: Fosinoprilat alleviates lipopolysaccharide (LPS) -induced inflammation by inhibiting TLR4/NF-

20. Wang YY and Li L: Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of 


22. Mairuae N, Hall Ii EC, Cheepsunthorn P, Lee SY and Connor JR: The H63D HFE gene variant promotes activation of the intrinsic 


40. Mairuae N, Hall Ii EC, Cheepsunthorn P, Lee SY and Connor JR: The H63D HFE gene variant promotes activation of the intrinsic 
